| |
Knight ADRC
|
ADNI1
|
ADNI2
|
BIOCARD
|
HB
|
Mayo
|
Sweden
|
UPenn
|
UW
|
|---|
|
n = 3146
|
805
|
390
|
397
|
184
|
105
|
433
|
293
|
164
|
375
|
|
Age (years)
|
70.39 ± 9.12
|
77.89 ± 6.89
|
73.28 ± 7.47
|
62.10 ± 9.46
|
67.52 ± 9.24
|
78.73 ± 6.35
|
75.15 ± 7.63
|
71.60 ± 8.98
|
62.35 ± 16
|
|
Age range (years)
|
37–91
|
58–93
|
55–92
|
23–86
|
45–84
|
50–95
|
50–88
|
50–94
|
21–88
|
|
Male (%)
|
46.09
|
60
|
54.91
|
41.53
|
54.29
|
60.51
|
37.54
|
41.46
|
50.67
|
|
APOE ε4 positive (%)
|
40.75
|
50
|
38.29
|
34.43
|
54.29
|
27.5
|
76.11
|
55.56
|
43.28
|
|
CDR > 0 (%)
|
29.34
|
71.28
|
71.03
|
5.43
|
–
|
22.17
|
100
|
62.8
|
33.33
|
|
Aβ42 levelsa
|
650.40 ± 305.59
|
169.83 ± 56.0
|
179.98 ± 51.31
|
386.90 ± 89.93
|
77.59 ± 23.30
|
331.0 ± 122.21
|
262.43 ± 72.77
|
163.55 ± 53.54
|
141.90 ± 41.42
|
|
p-tau181 levelsa
|
64.94 ± 34.26
|
34.13 ± 18.52
|
38.63 ± 21.21
|
38.94 ± 12.30
|
–
|
23.16 ± 10.55
|
105.76 ± 41.82
|
36.96 ± 26.80
|
56.56 ± 29.32
|
|
tau levelsa
|
372.40 ± 235.41
|
97.26 ± 52.03
|
79.69 ± 47.79
|
66.56 ± 26.60
|
84.27 ± 36.79
|
104.29 ± 58.06
|
782.20 ± 301.68
|
93.66 ± 54.29
|
61.64 ± 42.77
|
- aReported as mean ± standard deviation in pg/mL
- ADRC Alzheimer’s Disease Research Center, ADNI Alzheimer’s Disease Neuroimaging Initiative, APOE apolipoprotein E, BIOCARD Predictors of Cognitive Decline Among Normal Individuals, CDR Clinical Dementia Rating, HB Saarland University in Homburg/Saar, Germany, Mayo Mayo Clinic, Sweden Sahlgren’s University Hospital, Sweden, UPenn Perelman School of Medicine at the University of Pennsylvania, UW University of Washington
